FDA Staff Says GSK Is Missing Data On Pulmonary Drug
U.S. Food and Drug Administration staff on Friday cautioned an agency advisory committee against relying heavily on safety and efficacy data for GlaxoSmithKline PLC and Theravance Inc.'s proposed chronic obstructive pulmonary...To view the full article, register now.
Already a subscriber? Click here to view full article